The Role and Mechanism of the Histone Methyltransferase G9a in Tumors: Update

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-05-30 DOI:10.2147/ott.s451108

Hangsheng Zhou, Jiandong Gui, Lijie Zhu, Yuanyuan Mi

引用次数: 0

Abstract

Abstract: Methylation-mediated gene silencing is closely related to the occurrence and development of human tumors. The euchromatic histone lysine methyltransferase 2 (EHMT2, also known as G9a) is highly expressed in many tumors and is generally considered to be an oncogene, which is associated with the poor outcome of many tumors. Combined immunotherapy and immune checkpoint blockade therapy also have good efficacy and certain safety. However, there are still many difficulties in the drugs targeting G9a, and the combined effect and safety of G9a with many drugs is still under study. This article aims to summarize the role and mechanism of G9a and its inhibitors in tumors in the past two years, and to understand the application prospect of G9a from the perspective of diagnosis and treatment.

Keywords: cancer, G9a, methyltransferase, function, mechanism

查看原文本刊更多论文

组蛋白甲基转移酶 G9a 在肿瘤中的作用和机制最新进展

摘要：甲基化介导的基因沉默与人类肿瘤的发生和发展密切相关。半色素组蛋白赖氨酸甲基转移酶2（EHMT2，又称G9a）在许多肿瘤中高表达，被普遍认为是一种癌基因，与许多肿瘤的不良预后有关。联合免疫疗法和免疫检查点阻断疗法也具有良好的疗效和一定的安全性。然而，针对G9a的药物仍存在诸多难点，G9a与多种药物的联合作用及安全性仍在研究之中。本文旨在总结近两年来G9a及其抑制剂在肿瘤中的作用和机制，并从诊断和治疗的角度了解G9a的应用前景。关键词：肿瘤；G9a；甲基转移酶；功能；机制

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.